Search EFSA Journal
Refine your search
Type
All article types
Special Issue Item
Journal Editorial
Scientific opinions of Scientific/Scientific Panel
Opinion of the Scientific Committee/Scientific Panel
Statement of the Scientific Committee/Scientific Panel
Guidance of the Scientific Committee/Scientific Panel
Other scientific outputs of EFSA
Statement of EFSA
Guidance of EFSA
Conclusion on pesticides
Reasoned opinion on pesticide
Scientific report of EFSA
Technical Report
Subject
All subjects
Animal health & welfare
Biological hazards
Biological monitoring
Contaminants
Dietary & chemical monitoring
Emerging risks
Feed
Food Ingredients and Packaging
GMO
Nutrition
Pesticides
Plant health
Assessment and methodological support
Scientific Committee
Scientific cooperation
Article ID
Digital Object ID
Sort by:
Publication date
Relevance

Opinion of the Scientific Panel on Dietetic products, nutrition and allergies [NDA] related to the safety and suitability for particular nutritional use by infants of fructooligosaccharides in infant formulae and follow-on formulae

doi:10.2903/j.efsa.2004.31
  EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) Panel Members Wulf Becker, Daniel Brasseur, Jean-Louis Bresson, Albert Flynn, Alan A. Jackson, Pagona Lagiou, Geltrude Mingrone, Bevan Moseley, Andreu Palou, Hildegard Przyrembel, Seppo Salminen, Stefan Strobel and Hendrik van Loveren. Acknowledgment The Scientific Panel on Dietetic Products, Nutrition and Allergies wishes to thank Dominique Turck for his contribution to the draft opinion.
Type: Opinion of the Scientific Committee/Scientific Panel Question number: EFSA-Q-2003-020 Adopted: 19 February 2004 Published: 10 March 2004 Last updated: 31 January 2007. This version replaces the previous one/s.
Abstract

No abstract available

Summary

The request to assess the safety and suitability for particular nutritional use by infants of fructooligosaccharides in infant formulae and follow-on formulae has been evaluated by the Panel on the basis of data submitted and from the literature.

Data submitted included the reports on two studies: 1) a growth study in healthy infants fed with an infant formula supplemented with 1.5 or 3.0 g/L fructooligosaccharides; 2) a study of the faecal microbiota in healthy infants fed with an infant formula supplemented with 1.5 or 3.0 g/L fructooligosaccharides.

The data submitted indicate:

1. In the growth study, the anthropometric data suggest that the use of infant formula supplemented with either 1.5 or 3.0 g/L of fructooligosaccharides results in a normal growth pattern in healthy term infants less than two weeks of age for periods of up to twelve weeks. Serum markers of protein and mineral status and kidney function were also in the normal range.

2. No effect of fructooligosaccharides in rendering the faecal microbiota more similar to that in human milk-fed infants was demonstrated in infants fed an infant formula supplemented with either 1.5 or 3.0 g/L of fructooligosaccharides for one week.

3. Under the described conditions of use, fructooligosaccharides added to infant formula showed variable effects on consistency and frequency of stools. There was an increased prevalence of adverse effects, including loose stools, in infants fed formula with added fructooligosaccharides. As no measures were made to demonstrate satisfactory water balance, the possibility of increased risk of dehydration can not be excluded, raising concerns with respect to the safety of such formulae.

The Panel concludes that there is no evidence of benefits to infants from the addition of fructooligosaccharides to infant formula at the conditions specified by the manufacturer while there are reasons for safety concerns.

As no data have been submitted nor were available from the literature on the use of fructooligosaccharides in follow-on formula, the Panel is not in the position to evaluate the safety and suitability of FOS for such use.

Keywords

Opinion of the Scientific Panel on Dietetic products, nutrition and allergies [NDA] related to the safety and suitability for particular nutritional use by infants of fructooligosaccharides in infant formulae and follow-on formulae